Nationwide Children's News Releases
Viewing: 1-10 of 99 | All
Sep 22, 2026
FDA Approves First Gene Therapy Treatment for Sanfilippo Syndrome Type A, Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
The Abigail Wexner Research Institute at Nationwide Children’s Hospital celebrated the Food and Drug Administration’s (FDA) approval of FAYUVI™ for Sanfilippo Syndrome Type A, following years of research in its Jerry R. Mendell Center for Gene Therapy to help patients with devastating diseases.
Sep 10, 2026
Nationwide Children’s Hospital Receives Cellular Therapy Accreditation
Nationwide Children’s Hospital has received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT). Through demonstration of compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration, Nationwide Children’s has earned accreditation for its Biologics Manufacturing Resource, specifically its cellular therapy product processing with more than minimal manipulation.
Aug 21, 2026
Nationwide Children’s Becomes Qualified Treatment Center for Glycogen Storage Disease Type 1A Gene Therapy
Nationwide Children’s has been designated a qualified treatment center for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), a gene therapy for the treatment of glycogen storage disease type 1A (GSD Type 1A).
May 28, 2025
Nationwide Children’s Hospital Delivers its First Infusion of CASGEVY™ for Patient with Sickle Cell Disease
Nationwide Children’s Hospital delivered its first commercial infusion of CASGEVY™ to 17-year-old Carlos A. from Dayton, Ohio. Today, Carlos is thriving at home, pain-free.
Feb 03, 2025
Nationwide Children’s Hospital Researcher Receives Grant from the Rosenau Family Research Foundation
The Rosenau Family Research Foundation has awarded a three-year grant of $375,000 total in funding to Allison Bradbury, MS, PhD, along with collaborators at Cincinnati Children’s Hospital Medical Center and Auburn University, for studying in-utero gene therapy as a potential treatment for Krabbe disease and other lysosomal storage diseases.
Nov 07, 2024
Nationwide Children’s Hospital Receives a Wellstone Muscular Dystrophy Specialized Research Center Award from the NIH
Researchers in the Jerry R. Mendell, MD Center for Gene Therapy at Nationwide Children's Hospital have received a coveted P50 grant from the National Institutes of Health to establish a Wellstone Muscular Dystrophy Specialized Research Center (MDSRC).
Sep 10, 2024
Nationwide Children’s Hospital Renames Center for Gene Therapy, Honoring Jerry Mendell, MD
Nationwide Children’s Hospital announced today the renaming and dedication of the Jerry R. Mendell, MD Center for Gene Therapy at the Abigail Wexner Research Institute, in honor of Jerry Mendell, MD, a pioneer in the fields of neurology and gene therapy and a catalyst for advancement in the treatment of multiple neuromuscular disorders.
Jun 14, 2024
Nationwide Children’s Hospital Receives $25 Million Gift to Support Institute for Mental and Behavioral Health Research
Nationwide Children’s Hospital announced today that longtime donors Joe and Linda Chlapaty have donated $25 million to support the recently launched Institute for Mental and Behavioral Health Research. The gift will fund innovative research, endowed faculty to recruit nationally renowned researchers, and construction for new facilities.
Jan 18, 2024
Jerry Mendell, MD, Announced as King Faisal Prize Laureate in Medicine
Jerry Mendell, MD, senior advisor in the Center for Gene Therapy in the Abigail Wexner Research Institute at Nationwide Children’s Hospital, is this year’s recipient of the King Faisal Prize for Medicine for his contributions toward the screening, diagnosis and treatment of neuromuscular diseases, including spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and limb girdle muscular dystrophy.
Dec 11, 2023
Nationwide Children’s Hospital Becomes Authorized Treatment Center for Sickle Cell Gene Therapy
Nationwide Children’s Hospital has been designated an authorized treatment center for CASGEVY™ (exagamglogene autotemcel (exa-cel)), a gene therapy for the treatment of sickle cell disease.